VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer

This is a phase 1b/2 study, designed to evaluate the safety, tolerability, and efficacy of
VX15/2503 in combination with avelumab in subjects diagnosed with advanced (stage IIIB/IV)
NSCLC who have either progressed on first or second-line systemic anticancer therapy or who
have declined treatment with first or second-line system anticancer therapy. The primary
objective (Dose Escalation Phase) is to evaluate the safety and tolerability of ascending
doses of VX15/2503 Q2W in combination with avelumab 10mg/kg Q2W. The second primary objective
(Dose Expansion Phase) is to evaluate safety and tolerability of the recommended phase 2 dose
of VX15/2503 administered in combination with 10 mg/kg avelumab Q2W. The secondary objectives
include (Dose Expansion Phase), a preliminary estimate of efficacy using the following in
accordance with Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, Objective Response
(OR), Duration of Response (DoR) and Progression-Free Survival (PFS), as well as making a
preliminary estimate of efficacy using the following in accordance with iRECIST, OR, DoR and
PFS. Additional secondary objectives are to characterize the pharmacokinetics profile of
VX15/2503 and avelumab administered Q2W in combination, evaluate the immunogenicity of
VX15/2503 and avelumab administered Q2W and evaluate VX15/2503 and avelumab pharmacodynamics
markers including but not limited to receptor occupancy. Exploratory objectives include
identification of candidate biomarkers of activity and biomarkers that may predict response
to treatment with combination therapy of VX15/2503 and avelumab.

Enrollment will involve approximately 62 individuals who are 18 years of age or older with
advanced non-small cell lung cancer. The study will be divided into two phases, dose
escalation with up to 18 Immunotherapy naive subjects and dose expansion with up to 50
subjects (up to 22 subjects that are Immunotherapy naive and up to 28 subjects that have
failed on Immunotherapy). Subjects that are enrolled in the dose escalation phase may
continue into the dose expansion phase, as long as there is no evidence of disease
progression. The subjects entering the dose expansion phase from dose escalation, may have
their dose increased to the recommend phase 2 dose, once it is determined. Any subjects that
have evidence of disease progression will be taken off of treatment and will have a post
treatment safety follow-up visit 10 weeks after last treatment. Subjects that have
discontinued study drug will also continue to be followed every 3 months for survival, or
lost to follow-up. It is estimated that the study will take approximately 33 months between
first subject enrolled and last subject visit.

Inclusion Criteria:

1. Age > 18 years.

2. Signed informed consent prior to the performance of any study-specific procedures,
including fresh tumor biopsies.

3. Histologically or cytologically proven advanced (stage IIIB/IV) NSCLC subjects.
Subjects in the Dose Escalation Phase must be immunotherapy naïve.

4. i. Subjects in the Dose Escalation Phase must have either progressed on or declined
standard first-line therapy. Subjects with fewer than 3 lines of prior palliative
systemic anti-cancer therapy are eligible.

ii. Subjects in the Dose Expansion Phase must have progressed on a minimum of 2 cycles
of standard of care platinum-based chemotherapy with or without immunotherapy,
standard of care immunotherapy without chemotherapy or must have declined standard of
care first-line treatment options. Subjects with fewer than 3 lines of prior
palliative systemic anti-cancer therapy are eligible.

5. Subjects previously treated with systemic adjuvant/neoadjuvant therapy, other than
immunotherapy are also eligible for the Dose Escalation Phase. Subjects previously
treated with standard of care systemic adjuvant/neoadjuvant therapy are also eligible
for the Dose Expansion Phase.

6. Measureable disease as defined by the RECIST 1.1.

7. Availability of archival or fresh tumor specimen that is suitable for analysis.
Acceptable samples must have been acquired using core needle biopsy or excisional
biopsy. Samples that were acquired using fine needle aspiration are not acceptable.

8. Tumor lesion accessible for biopsy after the start of treatment. (Note: this lesion
should be separate from measurable lesions that will be used for response assessment.)

9. ECOG performance status (PS) score 0-1.

10. Left ventricular ejection fraction > 50%

11. Tumors lack activating epidermal growth factor receptor (EGFR) mutations, ROS-1, or
ALK rearrangement (no EGFR or ALK testing is required if a subject has a KRAS mutation
or squamous cell histology)..

12. Has adequate bone marrow, renal and hepatic function based upon laboratory tests as
follows:

- Absolute neutrophil count > 1500/µL

- Platelet count > 100 x 103/µL

- Hemoglobin > 9 g/dL, transfusion permitted

- Total bilirubin < 1.5 x upper limit of normal (ULN) (or < 3 x ULN for subjects
with Gilbert's syndrome)

- Creatinine clearance ≥ 50 mL/min on the basis of the Cockcroft-Gault glomerular
filtration rate calculation

- AST < 2.5 x ULN (5.0 x ULN in the presence of liver metastasis)

- ALT < 2.5 x ULN (5.0 x ULN in the presence of liver metastasis).

13. Highly effective contraception (i.e., methods with a failure rate of less than 1 % per
year) for both male and female subjects if the risk of conception exists (Note: The
effects of the trial treatment on the developing human fetus are unknown; thus, women
of childbearing potential and men must agree to use highly effective contraception,
defined in Protocol Appendix 9.3, or as stipulated in national or local guidelines.
Highly effective contraception must be used for the duration of trial treatment, and
at least for 60 days after stopping trial treatment or 6 months after stopping
chemotherapy [or per label]. Should a woman become pregnant or suspect she is pregnant
while she or her partner is participating in this trial, the treating physician should
be informed immediately).

Exclusion Criteria:

1. Prior therapy with any antibody or drug targeting T-cell coregulatory proteins (immune
checkpoints), such as PD-1, PD-L1, or cytotoxic T lymphocyte antigen-4 in the Dose
Escalation Phase only.

2. Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however,
alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety
risk based on Investigator's judgment are acceptable.

3. Concurrent anticancer treatment within 28 days before the start of trial treatment
(e.g., cytoreductive therapy, radiotherapy [with the exception of palliative bone
directed radiotherapy]; immune therapy, or cytokine therapy, except for
erythropoietin.

4. Major surgery within 28 days before the start of trial treatment (excluding prior
diagnostic biopsy); or use of any investigational drug within 28 days before the start
of trial treatment.

5. Subjects receiving immunosuppressive agents (such as steroids) for any reason should
be tapered off these drugs before initiation of the trial treatment (with the
exception of subjects with adrenal insufficiency, who may continue corticosteroids at
physiologic replacement dose, equivalent to ≤ 10 mg prednisone daily). Note: Previous
or ongoing administration of systemic steroids for the management of an acute allergic
phenomenon is acceptable as long as it is anticipated that the administration of
steroids will be completed in 14 days, or that the daily dose after 14 days will be
≤10 mg per day of prednisone or equivalent.

6. Previous malignant disease other than the target malignancy to be investigated in this
trial within the last 5 years (with the exception of adequately treated non-melanoma
skin cancers, carcinoma in situ of skin, bladder, cervix, colon/rectum, breast, or
prostate) unless a complete remission without further recurrence was achieved at least
2 years prior to study entry and the subject was deemed to have been cured with no
additional therapy required or anticipated to be required.

7. Rapidly progressive disease disease (i.e. disease progression before or at the time of
first tumor assessment, 8 - 12 weeks after initiation of systemic anti-cancer
therapy).

8. ECOG performance status score ≥ 2.

9. Women who are pregnant or breastfeeding.

10. History of pneumonitis or other interstitial lung disease

11. Active or history of any autoimmune disease including colitis and inflammatory bowel
disease (subjects with diabetes Type I, vitiligo, psoriasis, hypo- or hyperthyroid
disease not requiring immunosuppressive treatment are eligible) or immunodeficiencies.

12. Vaccination within 4 weeks of the first dose of avelumab and while on study is
prohibited except for administration of inactivated vaccines (e.g. inactivated
influenza vaccines).

13. Significant acute or chronic infection including, among others: Known history of human
immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome. Hepatitis B
virus (HBV) or hepatitis C virus (HCV) infection (defined as, HBV surface antigen
positive and HBV core antibody positive with reflex to positive HBV DNA or HBV core
antibody positive alone with reflex to positive HBV DNA or positive HCV antibody with
reflex to positive HCV RNA).

14. Central nervous system malignancy, the known presence of untreated or symptomatic CNS
metastases. Subjects with treated brain metastasis must be stable and off steroids and
anti-convulsants for at least 1 month prior to the start of study treatment. Subjects
with suspected brain metastases at Screening should have a CT/MRI of the brain prior
to study entry.

15. A history of hypersensitivity to other humanized monoclonal antibodies.

16. Significant cardiovascular disease (New York Heart Association Class II or greater),
myocardial infarction within the 6 months prior to study entry, unstable angina, or
cerebral vascular accident / stroke (< 6 months prior to enrollment), or serious
uncontrolled cardiac arrhythmia requiring medication / active intervention, corrected
QT interval [QTc] prolongation of >= 470ms and/or prior diagnosis of congenital long
QT syndrome.

17. Legal incapacity or limited legal capacity.

18. Current alcohol or drug abuse.

19. Any psychiatric condition that would prohibit the understanding or rendering of
informed consent.

20. Prior organ transplantation or allogeneic bone marrow transplantation.

21. Any uncontrolled medical condition (for example, inflammatory bowel disease,
uncontrolled asthma), which, in the opinion of the Investigator, might impair the
subject's tolerance of trial treatment or confound interpretation of study
assessments.

22. Inability to comply with visit schedule or other protocol requirements.